Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc
DUBLIN, Jan. 18, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the business combination of Jazz Pharmaceuticals, Inc. and Azur Pharma plc. The two companies have combined to create Jazz Pharmaceuticals plc, a specialty biopharmaceutical company based in Dublin, Ireland. Following the closing, Jazz Pharmaceuticals plc has approximately 60 million outstanding ordinary shares on a fully diluted basis.
"As Jazz Pharmaceuticals plc, we are a growing, profitable specialty biopharmaceutical company with a diverse portfolio of products in the central nervous system and women's health areas," said Bruce Cozadd, chairman and chief executive officer at Jazz Pharmaceuticals. "We now have a strengthened management team, a broader commercial organization and an efficient platform for further growth, with resources to build our product portfolio and a future pipeline."
Jazz Pharmaceuticals has approximately 430 employees, including a commercial organization focused around four key areas: narcolepsy, severe chronic pain, psychiatry and a diversified portfolio of women's health products. In addition to its headquarters in Dublin, Ireland, the company has offices in Palo Alto, California and Philadelphia, Pennsylvania.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, severe chronic pain, psychiatry and women's health. The company's marketed products in these areas include: Xyrem® (sodium oxybate), Prialt® (ziconotide intrathecal infusion), FazaClo® (clozapine USP) HD and LD, Luvox CR® (fluvoxamine maleate) and Elestrin® (estradiol gel 0.06%).
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals plc's growth potential and statements related the potential future product portfolio and pipeline of Jazz Pharmaceuticals plc, which are not historical facts. These forward-looking statements are based on Jazz Pharmaceuticals plc's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to risks associated with business combination transactions, such as the risk that the businesses will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; risks related to future opportunities and plans for Jazz Pharmaceuticals plc; disruption from the transaction, making it more difficult to conduct business as usual or maintain relationships with customers, employees or suppliers; and the possibility that if Jazz Pharmaceuticals plc does not achieve the perceived benefits of the transaction as rapidly or to the extent anticipated by financial analysts or investors, the market price of its shares could decline, as well as other risks related to Jazz Pharmaceuticals plc's business, including dependence on sales of Xyrem and the ability to increase sales of its products; competition, including potential generic competition; dependence on single source suppliers and manufacturers; the ability to protect intellectual property and defend patents; regulatory obligations and oversight; cash flow; and those other risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals, Inc.'s and Jazz Pharmaceuticals plc's SEC filings and reports, including, with respect to risks related to Jazz Pharmaceuticals Inc.'s historical business, in Jazz Pharmaceuticals, Inc.'s Quarterly Report on Form 10‑Q for the quarter ended September 30, 2011 and, with respect to risks related to Jazz Pharmaceuticals plc, in Jazz Pharmaceuticals Inc.'s definitive proxy statement filed with the SEC on November 10, 2011.
SOURCE Jazz Pharmaceuticals plc